Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone
1997

Inhibition of Prostate Cancer Growth by a Growth Hormone-Releasing Hormone Antagonist

Sample size: 60 publication Evidence: moderate

Author Information

Author(s): A Jungwirth, AV Schally, J Pinski, G Halmos, K Groot, P Armatis, M Vadillo-Buenfil

Primary Institution: Tulane University School of Medicine

Hypothesis

Can the GH-RH antagonist MZ-4-71 inhibit the growth of androgen-independent prostate cancers?

Conclusion

The GH-RH antagonist MZ-4-71 significantly inhibits the growth of androgen-independent prostate cancers in animal models.

Supporting Evidence

  • MZ-4-71 reduced tumor volume in DU-145 and PC-3 prostate cancers significantly.
  • Serum levels of GH and IGF-I were significantly decreased in treated animals.
  • Treatment with MZ-4-71 prolonged tumor doubling time in both DU-145 and PC-3 tumors.

Takeaway

A new medicine called MZ-4-71 can help stop the growth of certain prostate cancers in mice.

Methodology

The study involved treating nude mice and rats with the GH-RH antagonist MZ-4-71 and measuring tumor growth and hormone levels.

Limitations

The study was conducted in animal models, which may not fully represent human responses.

Participant Demographics

Male athymic nude mice and Copenhagen rats were used in the study.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication